New option for the treatment of hyperbilirubinemia: In vitro direct hemoperfusion with the lixelle S-35

International Journal of Artificial Organs

Volumn 37, Issue 11, 2014, Pages 816-823

  Sartori, Marco ^a,b,c   Sharma, Aashish ^a,b,d   Neri, Mauro ^a,b   Garzotto, Francesco ^a,b   Nalesso, Federico ^a,b   Giavarina, Davide ^b   Zancato, Mirella ^c   Ronco, Claudio ^a,b  

^a International Renal Research Institute Vicenza (IRRIV)   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d INDRAPRASTHA APOLLO HOSPITAL   (India)

Author keywords

Adsorption; Bilirubin removal; Direct hemoperfusion; Extracorporeal system; Liver support; Lixelle

Indexed keywords

BLOOD;

ACUTE LIVER FAILURE; ACUTE-ON-CHRONIC LIVER FAILURE; BILIRUBIN REMOVAL; DIRECT HEMOPERFUSION; EXTRACORPOREAL SYSTEMS; HEMOPERFUSION; HYPERBILIRUBINEMIA; IN-VITRO; LIVER SUPPORT; LIXELLE;

ADSORPTION;

BETA 2 MICROGLOBULIN; BILIRUBIN GLUCURONIDE; BILIRUBIN; BIOLOGICAL MARKER;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ADSORPTION KINETICS; ALBUMIN DIALYSIS; AMYLOIDOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; DETOXIFICATION; EXTRACORPOREAL CIRCULATION; FLOW RATE; HEMOPERFUSION; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; LIXELLE S 35; MEDICAL DEVICE; ACUTE-ON-CHRONIC LIVER FAILURE; ADSORPTION; BIOLOGICAL MODEL; BLOOD; DEVICES; EQUIPMENT DESIGN; EVALUATION STUDY; LIVER FAILURE, ACUTE; MATERIALS TESTING; TIME; UPREGULATION;

ACUTE-ON-CHRONIC LIVER FAILURE; ADSORPTION; BILIRUBIN; BIOLOGICAL MARKERS; EQUIPMENT DESIGN; HEMOPERFUSION; HUMANS; HYPERBILIRUBINEMIA; LIVER FAILURE, ACUTE; MATERIALS TESTING; MODELS, BIOLOGICAL; TIME FACTORS; UP-REGULATION;

EID: 84924803992     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000363     Document Type: Article

References (23)

1. Trey C, Davidson CS. The management of fulminant hepaticfailure. Prog Liver Dis. 1970;3:282-298.
2. Sen S, Williams R, Jalan R. The pathophysiological basis ofacute-on-chronic liver failure. Liver. 2002;22(Suppl 2):5-13.
3. Sen S, Williams R, Jalan R. Emerging indications for albumindialysis. Am J Gastroenterol. 2005;100(2):468-475.
4. Kellum JA, Song M, Venkataraman R. Hemoadsorption removestumor necrosis factor, interleukin-6, and interleukin-10,reduces nuclear factor-kappaB DNA binding, and improvesshort-term survival in lethal endotoxemia. Crit Care Med.2004;32(3):801-805.
5. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorptionon cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36(5):1573-1577.
6. Oda S, Hirasawa H, Shiga H, et al. Cytokine adsorptiveproperty of various adsorbents in immunoadsorption columnsand a newly developed adsorbent: an in vitro study. Blood Purif. 2004;22(6):530-536.
7. Ronco C, Garzotto F, Brendolan A, et al. Continuous renalreplacement therapy in neonates and small infants: developmentand first-in-human use of a miniaturised machine(CARPEDIEM). Lancet. 2014;383(9931):1807-1813.
8. Kuang D, Chionh CY, Cruz DN, Ronco C. Sorbent From BasicStructure to Clinical Application. In: Ronco C, Bellomo R, Kellum J. Critical Care Nephrology. 2nd ed. Philadelphia, PA:Elsevier Health; 2009:1524-1535.
9. Furuyoshi S, Nakatani M, Taman J, Kutsuki H, Takata S, Tani N. New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion. Ther Apher. 1998;2(1):13-17.
10. Evans TW. Review article: albumin as a drug—biologicaleffects of albumin unrelated to oncotic pressure. Aliment PharmacolTher. 2002;16(Suppl 5):6-11.
11. O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, HughesRD, Williams R. Controlled trials of charcoal hemoperfusionand prognostic factors in fulminant hepatic failure. Gastroenterology.1988;94(5 Pt 1):1186-1192.
12. Tsuchida K, Takemoto Y, Nakamura T, et al. Lixelle adsorbentto remove inflammatory cytokines. Artif Organs. 1998;22(12):1064-1067.
13. Tsuchida K, Takemoto Y, Sugimura K, Yoshimura R, Yamamoto K, Nakatani T. Adsorption of endotoxin by beta 2- microglobulin adsorbent column (Lixelle): the new approach for endotoxinemia. Thera Apher. 2002;6(2):116-118.
14. Tsuchida K, Takemoto Y, Nakatani T, Nakamura T, SugimuraK, Yamamoto K. Adsorption of microorganism componentsby lixelle beads. Artif Organs. 2000;24(7):577-580.
15. National Center for Biotechnology Information. PubChemCompound Database; CID= 5280352. Page https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5280352. AccessedAugust 18, 2014.
16. National Center for Biotechnology Information. PubChemCompound Database; CID= 6438344. Page. https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6438344.Accessed August 18, 2014.
17. National Center for Biotechnology Information. PubChemCompound Database; CID = 5280817. Page. https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5280817.Accessed August18, 2014.
18. Bonnett R, Davies JE, Hursthouse MB. Structure of bilirubin. Nature. 1976;262(5566):327-328.
19. Sauer IM, Goetz M, Steffen I, et al. In vitro comparison of themolecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology. 2004;39(5):1408-1414.
20. Falkenhagen D, Strobl W, Vogt G, et al. Fractionated plasmaseparation and adsorption system: a novel system forblood purification to remove albumin bound substances.Artif Organs. 1999;23(1):81-86.
21. La Greca G, Brendolan A, Ghezzi PM, et al. The conceptof sorbent in hemodialysis. Int J Artif Organs. 1998;21(6):303-308.
22. Kribben A, Gerken G, Haag S, et al. Effects of fractionatedplasma separation and adsorption on survival in patientswith acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782-789.e3.
23. Bañares R, Nevens F, Larsen FS, et al; RELIEF study group.Extracorporeal albumin dialysis with the molecular adsorbentrecirculating system in acute-on-chronic liver failure:the RELIEF trial. Hepatology. 2013;57(3):1153-1162.